Bayer considers expanding use of Nubeqa on new data from prostate cancer trial
Bayer said its drug Nubeqa was shown to slow the progression of a certain type of prostate cancer in a late-stage trial, bolstering growth prospects for one of the German drugmaker’s key pharmaceuticals. The drug is already approved in other prostate cancer treatments.
BELIEBTE BEITRÄGE
UK sets new climate target for 2035
November 13, 2024
Children go back to school after Valencia floods
November 13, 2024
Researchers document huge decline in African elephants
November 13, 2024
Mission: Impossible 8 title revealed
November 13, 2024
LIVEÜBERTRAGUNG